Naloxone Overdose Death Antidote Spikes In Price

Naloxone Overdose Death Antidote Spikes In Price

February 16th, 2017 in Addiction

Naloxone Unjustifiable Price

The United States is currently in a crisis with the Opioid Epidemic reaching the detrimental point that it has.

Reports from the Centers of Disease Control and Prevention indicate that more than half a million-people have died from a drug overdose between 2000 and 2015. Over six out of ten drug overdose deaths involved an Opioid.

This terrifying number of fatal overdoses involves Heroin, prescription Painkillers and other synthetic Opioids.

According to the Prescription Drug Abuse Policy System many American deaths are preventable through Administration of a “relatively cheap, safe and effective drug, Naloxone hydrochloride.”

Within the last few years, the Federal government has issued a public health crisis to put preventative measures in place and broaden the access of this overdose antidote.

Naloxone, in its most generic form, has been on the market since 1971, although only approved to use in a medical professional setting until now.

The Federal government also issued initiatives to expand access to communities across the nation, however, the expansion per state is left up to each state’s discretion.

How Much Does It Cost to Save a Life?

Millions in government funding have been spent in equipping law enforcement and other first responders with the overdose antidote Naloxone, but communities within the U.S. are seeking preparation as well.

Schools, libraries, fast-food restaurants and even coffee shops are seeking this life-saving drug to have just in case. If that doesn’t speak volumes, I’m not sure what will.


By June of 2016, all U.S. states except for Kansas, Montana and Wyoming passed legislation specifically designed to improve Naloxone access to the public.

Due to the high increases in demand, this seemingly cheap drug in its auto-inject form has reached unaffordable and unreasonable prices.

Big Pharma: Profiting on Opioid Health Crisis

Kaleo, a Virginia pharmaceutical company, founded by twin brothers Evan and Eric Edwards, is the manufacturer of the auto-injector device and overdose antidote, Evzio.

There is no surprise, when it comes to pharmaceutical companies hiking cardinal drug prices. When a demand increases, so does the price, even with drugs that are imperative to saving someone’s life.

Identically, Kaleo has joined the game, raising a twin pack of Evzio from $690 in 2014, when it was approved by the Federal Drug Administration, to $4,500 this year.

Per Kaleo, the audio and visual guiding components of Evzio ensure easy usage, which makes it worth the price. However, there are other forms of Naloxone that are more consumer price friendly and can be administered by everyday people.

Evzio’s Naloxone Auto-injector Coupons and Prescriptions

In attempt to make Evzio a trusted brand, Kaleo dispensed much of the product for free, giving away over 180,000 devices. According to Mark Herzog, vice president of the Kaleo corporate affairs, the devices were distributed to nearly 250 organizations among 34 states.

The organizations included police departments, as well as nonprofits that distribute the drug to at risk individuals. Kaleo’s donatable supply was exhausted by July in 2016.


Even though, the idea of Evzio is great and essentially makes saving a person’s life as simple as sending a text or pressing a button, few people can afford it.

Statements from the company indicate that Evzio consumers are not in as much of a financial hardship as perceived from the recent price hike backlash.

The company provides coupons to privately insured patients, resulting in a zero copay when picking up the overdose reversal device, so the lack of availability due to prices is debatable.

Affirmed by the Scientific American, Herzog states that the devices are a necessity to subsidized programs that don’t have co-payments. In a follow-up email, Herzog also claimed that the product listing price is “not a true gauge,” considering insurance companies often negotiate discounts and rebates.

To reflect on Herzog’s statements, Evzio is of limited access across the board and without a prescription is impossible to realistically afford.

The opportunity to get Evzio free or at a steep discount is possible for private organizations and few government agencies, however it is not for the general public. For individuals who are unable to obtain such a discount on the drug, the cost ultimately eliminates access.

Alternative Naloxone for Opioid Overdose Reversal

The immediate, easy-to-use auto-injector form of Naloxone, is not the only product on the market. Aside from Kaleo, there are four other pharmaceutical companies that produce Naloxone- Amphastar, Pfizer, Adapt and Mylan.


The high price runner up of an easy-to-use version of the drug is Narcan, a nasal spray made by Adapt Pharma. Most importantly, the cheapest forms of Naloxone are made by Amphastar, Mylan and Pfizer (Hospira).

In January 2015, Amphastar’s version of injectable Naloxone increased from $12 in 2001, to $41 per dose.

Pfizer Pharmaceutical purchased Hospira in 2015 and reports from Truven Health Analytics show that Hospira’s version of the drug was only $0.92 a dose in 2005 and jumped to $15.80 in October of 2014.

Narcan the Naloxone nasal spray is about $63 a dose, only a fragment of Kaleo’s auto-injector cost.

However, according to Adapt’s chief commercial officer, Matt Ruth, the company does offer the product for nearly half the list price to communal organizations, uninsured patients and government agencies.

As stated by IMS Health, the overall increasing demand has pushed Naloxone sales to incredible heights. Naloxone sale were at $81.9 million in 2015, up from the $21.3 million in 2011.

Although, an easy-to-use version of Naloxone may be perceived to alleviate stress when facing an Opioid overdose, the price ultimately stop this alleviation from happening altogether.

Whether you can afford an easy-to-use auto-injector, such as Evzio or not, the Naloxone antidote itself is obtainable from other manufacturers and is much more affordable.

No Comments

Post A Comment